Publications

5808 Results

Impact of supplemental site grants to increase African American accrual for the selenium and vitamin e cancer prevention trial

Authors
E Cook;K Arnold;J Hermos;W McCaskill-Stevens;S Moody-Thomas;J Probstfield;S Hamilton;R Campbell;K Anderson;L Minasian
Journal / Conference
Society of Clinical Trials Annual Meeting, abst. P104; poster
Year
2010
Research Committee(s)
Prevention, Screening, and and Surveillance
Study Number(s)
S0000

Diffuse large B-cell lymphomas with high grade morphologic features and/or MYC translocations lack distinctive clinicopathologic features at presentation: a SWOG S9704 study

Authors
J Cook;R Tubbs;L Rimsza;P Stiff;M LeBlanc;R Fisher;B Goldman
Journal / Conference
United States and Canadian Academy of Pathology 99th Annual Meeting, abst #1308 (3/20-26, 2010, Wash DC); poster
Year
2010
Research Committee(s)
Lymphoma
Study Number(s)
S9704

Simple oral therapy with capecitabine (CAPE) and cyclophosphamide (CPA) for metastatic breast cancer

Authors
A Schott;D Lew;W Barlow;K Albain;H Chew;J Wade;K Lanier;H Linden;G. Hortobagyi;R Livingston
Journal / Conference
Journal of Clinical Oncology 28:7s (suppl; 1006); ASCO 2010 Annual Meeting; oral
Year
2010
Research Committee(s)
Breast
Study Number(s)
S0430

Single nucleotide differences (SNDs) in the dbSNP database may lead to errors in genotyping and haplotyping studies. PMC2797835; PMID:19877174

Authors
L Musumeci;J Arthur;F Cheung;A Hoque;S Lippman;J Reichardt
Journal / Conference
Human Mutation 31(1):67-73
Year
2010
Research Committee(s)
Cancer Control
Study Number(s)
SWOG-9217

Video productions in SELECT: effective tools for staff learning and participant motivation in clinical trials

Authors
JM Harris-Talley;D Arney;K Anderson;JA Hartline
Journal / Conference
Society for Clinical Trials 2010 Meeting; poster
Year
2010
Research Committee(s)
Prevention, Screening, and and Surveillance
Study Number(s)
S0000

Should unknown primary melanomas be excluded from adjuvant therapy trials? Insights from the SWOG S0008 phase III randomized adjuvant trial

Authors
V Sondak;R Tuthill;J Moon;JA Thompson;C Lao;B Redman;LE Flaherty
Journal / Conference
Journal of Clinical Oncology 28:7s (suppl; abstr 8517) ASCO 2010 Meeting; poster
Year
2010
Research Committee(s)
Melanoma
Study Number(s)
S0008

Evaluation of minimal residual disease (MRD) in peripheral blood (PB) assessed prospectively by RT-PCR for melanoma-associated genes is an independent prognostic factor for survival in stage III melanoma (mel) patients (pts) enrolled onto an intergroup adjuvant trial S0008

Authors
J Sosman;J Moon;PY Liu;L Flaherty;MB Atkins;K Margolin;J Kirkwood;V Sondak
Journal / Conference
Journal of Clinical Oncology 28:7s (suppl; abstr 8513); ASCO 2010 Meeting; poster
Year
2010
Research Committee(s)
Melanoma
Study Number(s)
S0008

Paclitaxel-gemcitabine (P-G) for patients (pts) with advanced (adv) urothelial cancer (UC), aged > 70 years 9yrs): SWOG 0028

Authors
D Raghavan;C Tangen;C Moinpour;C Gotay;K Albain;S Louie;HJ Lenz;DI Quinn;MHA Hussain;IM Thompson
Journal / Conference
Journal of Clinical Oncology 28:7s (suppl; abstr 4569); ASCO 2010 Meeting; poster
Year
2010
Research Committee(s)
Genitourinary
Study Number(s)
S0028

A phase II trial of biweekly gemcitabine and paclitaxel (GEMTAX) with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN): A Southwest Oncology Group study

Authors
KE Bickel;J Moon;O Kucuk;RH Wheeler;S Urba;G Wolf;FP Worden
Journal / Conference
Journal of Clinical Oncology 28:7s (suppl; abstr 5555); ASCO 2010 Meeting; poster
Year
2010
Research Committee(s)
Head and Neck
Study Number(s)
S0329

Circulating tumor cell capture and analysis in a multi-center SWOG-coordinated prostate cancer trial

Authors
A Goldkorn;T Xu;B Lu;A Williams;LM Fink;C Tangen;YC Tai;DI Quinn;P Twardowski;RJ Cote
Journal / Conference
Journal of Clinical Oncology 28:7s, 2010 (suppl;abstr TPS342); ASCO; poster
Year
2010
Research Committee(s)
Genitourinary
Study Number(s)
S0421